Supplier
Special Care Pharmacy Services, LLC
Special Care Pharmacy Services, LLC was paid $12.90M by Medicaid between Jan 2018 and Nov 2024, across 28 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 60% of everything it billed.
33Billing provider infoSPECIAL CARE PHARMACY SERVICES, LLC
SAN JUAN, PR 00925
SAN JUAN, PR 00925
33aNPI1205819729assigned 11/29/2005
33bProvider typeDialysis Equipment & Supplies (DME)
28Total paid$12.90M
24GClaims15,519
24DCodes billed28
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 922 | $550K | |
| 2019 | 3,015 | $2.41M | |
| 2020 | 415 | $140K | |
| 2021 | 1,632 | $1.37M | |
| 2022 | 3,321 | $2.49M | |
| 2023 | 3,897 | $3.06M | |
| 2024incomplete | 2,317 | $2.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 60% | 3,849 | 1,978 | $7.72M |
| J9035 | Injection, bevacizumab, 10 mg | 8.7% | 183 | 149 | $1.12M |
| J9271 | Injection, pembrolizumab, 1 mg | 7.1% | 79 | 68 | $918K |
| J9395 | Injection, fulvestrant, 25 mg | 5.5% | 476 | 211 | $713K |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 4.9% | 136 | 95 | $631K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 4.3% | 91 | 82 | $552K |
| J0897 | Injection, denosumab, 1 mg | 3.6% | 218 | 203 | $465K |
| J9312 | Injection, rituximab, 10 mg | 1.2% | 21 | 17 | $152K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.2% | 130 | 127 | $149K |
| T1030 | Nursing care, in the home, by registered nurse, per diem | 1.0% | 2,469 | 667 | $133K |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | <1% | 16 | 12 | $111K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 20 | 13 | $53K |
16 more codes
| J9070 | Cyclophosphamide, 100 mg | <1% | 90 | $50K |
| S9379 | Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | <1% | 1,645 | $47K |
| J9306 | Injection, pertuzumab, 1 mg | <1% | 20 | $41K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 120 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,412 | $5K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 17 | $5K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 46 | $5K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 210 | $4K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 39 | $4K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 64 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 850 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,161 | $3K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 426 | $2K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 110 | $2K |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 18 | $510.00 |
| S0028 | Injection, famotidine, 20 mg | <1% | 603 | $229.22 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROJAS, JOSE (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Professional Infusion Center, INC. | San Juan, PR | $493K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.